Bird & Bird advises Genetic Signatures Limited on its successful placement and rights issue raising AUD$16 million

Bird & Bird is pleased to have advised Genetic Signatures Limited, an Australian Securities Exchange listed and Australian-based global molecular diagnostics company, on its successful placement and rights issue to raise approximately AUD$16 million (“Capital Raise”).

The Capital Raise was constituted by an AUD$8 million institutional placement and a fully underwritten AUD$8 million pro-rata non-renounceable rights issue to existing shareholders.

Proceeds from the Capital Raise will be used to fund growth initiatives including US regulatory clearances, US product launches, new instrument development and working capital.

Bird & Bird's team was led by Corporate partner Chris Clarke supported by associate Carl Ritchie.

Chris Clarke comments: “We were delighted to assist Genetic Signatures on this important capital raising, which proves that good businesses can still attract funding notwithstanding difficult capital markets.”  


News & Deals

More News & Deals

Deal

Bird & Bird advised the African Development Bank on $100 million financing of Sucden

Feb 04 2025

Read More

News

Bird & Bird hires Susan Battye to lead the employment practice in Ireland

Jan 28 2025

Read More

Deal

Bird & Bird and Sheppard Mullin Represent Buyers in the Majority Sale of Championship Football Club, Swansea City AFC

Jan 27 2025

Read More

Deal

Bird & Bird advised Bpifrance’s Large Venture on Series A financing round of Bioptimus, a specialist in AI applied to innovation in biomedicine

Jan 22 2025

Read More

Deal

Bird & Bird advises A.T. Kearney on the acquisition of Project Partners Management GmbH

Jan 22 2025

Read More

Deal

Bird & Bird advises RIVE on an additional €270 million bank financing

Jan 21 2025

Read More